Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,297.32
(
-0.06%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 194247

Wednesday, 11/11/2015 8:46:40 AM

Wednesday, November 11, 2015 8:46:40 AM

Post# of 257300
EGRX had $96.0M of cash at 9/30/15, implying a cash burn of $7.7M during 3Q15:

http://finance.yahoo.com/news/eagle-pharmaceuticals-inc-reports-third-120000606.html

EGRX will soon be profitable, assuming the NDA for rapid-infusion Bendamustine partnered with Teva is approved by the FDA by the PDUFA date of 12/13/15.

EGRX also has a PDUFA date for alcohol-free Docetaxel (licensed from Teikoku Pharma) on 12/26/15 (#msg-118114979).

Further, EGRX expects to report data from the Ryanodex heatstroke trial during December (#msg-117506124).

The PDUFA date for EGRX’s ready-to-use Angiomax is 3/20/16.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today